Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03974022 |
Recruitment Status :
Active, not recruiting
First Posted : June 4, 2019
Last Update Posted : May 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Small Cell Lung Cancer | Drug: Sunvozertinib | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 315 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation |
Actual Study Start Date : | July 9, 2019 |
Estimated Primary Completion Date : | July 2024 |
Estimated Study Completion Date : | July 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A Dose escalation |
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part A Dose expansion cohort 1 |
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part A Dose expansion cohort 2 |
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part A Dose expansion cohort 3
Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
|
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part A Dose expansion cohort 4
Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
|
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part A Dose expansion cohort 5
Patients with EGFR Exon20ins, treatment naïve
|
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part A Dose expansion cohort 6 |
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part B Dose extension cohort 1
Patients with EGFR Exon20ins
|
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
Experimental: Part B Dose extension cohort 2
Patients with EGFR Exon20ins
|
Drug: Sunvozertinib
Daily dose of Sunvozertinib
Other Name: DZD9008 |
- Part A: Safety and tolerability of Sunvozertinib. [ Time Frame: 28 days after the first multiple dose ]To investigate the safety and tolerability of Sunvozertinib when given orally to patients with advanced NSCLC with EGFR or HER2 mutations; To establish Maximum Tolerated Dose (MTD) (if possible) and Recommended Phase 2 Dose (PR2D) of Sunvozertinib when given orally in patients with advanced NSCLC with EGFR or HER2 mutations.
- Part B: Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC). [ Time Frame: through the study completion, an average of around 1 year ]To evaluate anti-tumor activity of Sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion at defined dose(s) by assessment of Objective Response Rate (ORR).
- Part A: Plasma and urine Sunvozertinib concentrations, and derived PK parameters. [ Time Frame: Through cycle 3 day 1 (8 days for Cycle 0, 28 days for Cycle 1, then 21 days for each subsequent cycle) ]To characterize the pharmacokinetics (PK) of Sunvozertinib following a single oral dosing and at steady state after multiple oral dosing in the fasted state, and renal excretion of Sunvozertinib.
- Part A: Plasma Sunvozertinib concentrations, and derived PK parameters [ Time Frame: Through the study completion ]To evaluate the effect of food on the exposure of Sunvozertinib at the defined doses.
- Part A: ORR, BOR, DoR, DCR, %change in size of tumor lesion, PFS by investigator. [ Time Frame: Through the study completion ]To assess preliminary anti-tumor activity of Sunvozertinib according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator.
- Part A: ORR, DCR, DoR by IRC. [ Time Frame: Through the study completion ]To retrospectively assess anti-tumor activity of Sunvozertinib in patients with EGFR Exon20ins according to RECIST 1.1 by an Independent Review Committee (IRC).
- Part B: DoR, PFS, DCR, BOR and % of change in size of tumor lesion according to RECIST 1.1 using assessments performed by an IRC; DoR, PFS, DCR, BOR and % of change in size of tumor lesion using investigators assessments accord. [ Time Frame: Through the study completion ]To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.
- Part B: AEs/SAEs; Laboratory data; vital signs; physical examination; ECG; echocardiogram/MUGA; pulmonary function test. [ Time Frame: Through the study completion ]To determine the safety and tolerability of Sunvozertinib.
- Part B: Plasma Sunvozertinib and metabolite concentration and derived PK parameters if deemed appropriately. [ Time Frame: Through the study completion ]To characterize the PK of Sunvozertinib.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged at least 18 years old, be able to provide a signed and dated, written informed consent.
- With documented histological or cytological confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations.
- (ECOG) performance status 0-1.
- Predicted life expectancy ≥ 12 weeks
- Patient must have measurable disease according to RECIST 1.1.
- Patients with brain metastasis (BM) can be enrolled under the condition that BM is previously treated and stable, neurologically asymptomatic and does not require corticosteroid treatment.
- Adequate organ system function.
-
Part A Dose expansion: Dose expansion cohort 5: NSCLC patients with EGFR Exon20ins, who have not received prior systemic therapy (treatment naïve).
Part B Dose extension:
- Patients must have histologically or cytologically confirmed locally advanced or metastatic NSCLC with documented EGFR Exon20ins mutation in tumor tissue from a local CLIA-certified laboratory (or equivalent) or Sponsor designated central laboratory prior to the study entry.
- Patients should have received at least 1 line, but no more than 3 lines of systemic therapy for metastatic/locally advanced disease.
Exclusion Criteria:
- For part B: Patients who have received prior treatment with Poziotinib or TAK788 or other EGFR/HER2 exon20 insertion inhibitors should be excluded. Prior treatment with currently approved EGFR TKIs for sensitizing or T790M resistance mutations, such as gefitinib, erlotinib, osimertinib, afatinib and dacomitinb, are allowed unless the patient had an objective response and subsequent progression assessed by the investigator.
- Treatment with EGFR or HER2 antibodies, major surgery (excluding placement of vascular access), or onco-immunotherapy (e.g. immune checkpoint inhibitors PD-1, PD-L1, CTLA-4) within 4 weeks before the first administration of Sunvozertinib.
- Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before the first administration.
- Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose or with a wide field of radiation which must be completed within 4 weeks before the first administration.
- Receiving (or unable to stop using) medications or herbal supplements known to be potent inhibitors or inducers of CYP3A within 1-2 weeks before the first administration.
- Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting Sunvozertinib with the exception of alopecia and grade 2 prior platinum-therapy related neuropathy.
- Spinal cord compression or leptomeningeal metastasis.
- As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C, human immunodeficiency virus (HIV) and COVID-19 (per local practice).
- Any of the following cardiac criteria: (1) Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms (ECGs); (2) Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec. (3) Any factors that increase the risk of QTF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval; (4) Prior history of atrial fibrillation within 6 months of first administration of Sunvozertinib, except prior drug treatment related and recovered.
- Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Sunvozertinib.
- History of hypersensitivity to active or inactive excipients of Sunvozertinib or drugs with a similar chemical structure or class to Sunvozertinib.
- Women who are pregnant or breast feeding.
- Involvement in the planning and conduct of the study.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03974022
Principal Investigator: | Pasi Antero Jänne, M.D & Ph. D | Dana-Farber Cancer Institute |
Responsible Party: | Dizal Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT03974022 |
Other Study ID Numbers: |
DZ2019E0001 |
First Posted: | June 4, 2019 Key Record Dates |
Last Update Posted: | May 15, 2024 |
Last Verified: | May 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Non-Small Cell Lung Cancer EGFR HER2 mutation |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |